Alkermes (NASDAQ:ALKS) EVP Craig Hopkinson Sells 3,748 Shares of Stock

Alkermes plc (NASDAQ:ALKS) EVP Craig Hopkinson sold 3,748 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $30.00, for a total transaction of $112,440.00. Following the completion of the transaction, the executive vice president owned 65,740 shares in the company, valued at $1,972,200. This trade represents a 5.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Alkermes Stock Up 0.8%

Shares of ALKS opened at $29.52 on Friday. Alkermes plc has a 52 week low of $25.17 and a 52 week high of $36.45. The stock has a market cap of $4.87 billion, a price-to-earnings ratio of 14.61, a PEG ratio of 1.41 and a beta of 0.49. The business has a 50-day simple moving average of $30.45 and a two-hundred day simple moving average of $29.37.

Alkermes (NASDAQ:ALKS) last issued its earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.08. The company had revenue of $394.19 million during the quarter, compared to the consensus estimate of $355.23 million. Alkermes had a net margin of 22.27% and a return on equity of 21.81%. Alkermes’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.73 EPS. Alkermes has set its FY 2025 guidance at 1.360-1.470 EPS. On average, equities analysts anticipate that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alkermes

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Swiss Life Asset Management Ltd purchased a new position in shares of Alkermes during the 3rd quarter worth $221,000. CIBC Bancorp USA Inc. acquired a new position in Alkermes in the third quarter valued at about $519,000. Centaurus Financial Inc. lifted its position in Alkermes by 20.7% in the third quarter. Centaurus Financial Inc. now owns 5,602 shares of the company’s stock valued at $168,000 after buying an additional 960 shares during the last quarter. Danske Bank A S purchased a new position in Alkermes during the third quarter worth about $1,004,000. Finally, XTX Topco Ltd acquired a new stake in shares of Alkermes during the third quarter valued at about $1,339,000. Institutional investors own 95.21% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on ALKS shares. Needham & Company LLC raised their target price on shares of Alkermes from $43.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Wells Fargo & Company dropped their price objective on shares of Alkermes from $42.00 to $37.00 and set an “overweight” rating for the company in a research note on Thursday, November 13th. Zacks Research cut shares of Alkermes from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. Piper Sandler reiterated an “overweight” rating and issued a $45.00 price target (up previously from $38.00) on shares of Alkermes in a research report on Thursday, October 23rd. Finally, Weiss Ratings raised Alkermes from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $44.69.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.